European Journal of Nuclear Medicine and Molecular Imaging最新文献

筛选
英文 中文
Persistent somatostatin PET signs of inflammatory cells 4 to 5 months after acute myocarditis are linked to a poorer recovery of cardiac function
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-22 DOI: 10.1007/s00259-025-07202-5
Thomas Larive, Caroline Boursier, Marine Claudin, Jeanne Varlot, Laura Filippetti, Olivier Huttin, Véronique Roch, Laetitia Imbert, Matthieu Doyen, Antoine Fraix, Damien Mandry, Elodie Chevalier, Pierre-Yves Marie
{"title":"Persistent somatostatin PET signs of inflammatory cells 4 to 5 months after acute myocarditis are linked to a poorer recovery of cardiac function","authors":"Thomas Larive, Caroline Boursier, Marine Claudin, Jeanne Varlot, Laura Filippetti, Olivier Huttin, Véronique Roch, Laetitia Imbert, Matthieu Doyen, Antoine Fraix, Damien Mandry, Elodie Chevalier, Pierre-Yves Marie","doi":"10.1007/s00259-025-07202-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07202-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Acute Myocarditis (AM) was recently shown to be detected by the Somatostatin Positron Emission Tomography (PET) criterion of &gt; 18 cm<sup>3</sup> Myocardial Uptake Volume (MUV), a sign of significant inflammatory cell infiltration. This study characterizes patients for whom this criterion persists 4 to 5 months after AM.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Cardiac Magnetic Resonance (CMR) and [<sup>68</sup> Ga]Ga-DOTA-TOC PET data from 27 AM patients (2 women, median age 26.5 years [interquartile range: 21.9–31.9]) were analyzed at the acute phase and at a 4.5 [4.3–5.0] month follow-up.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Eleven AM patients (41%) still had &gt; 18 cm<sup>3</sup> MUV at the follow-up (PET +). The left ventricular ejection fraction (LVEF) was correlated with MUV at baseline (<i>p</i> = 0.011) and follow-up (<i>p</i> = 0.001) and was lower at follow-up in PET + (52.9 [48.6; 55.0] %) than in the other patients (56.0 [54.3; 57.8] %, <i>p</i> = 0.001). However, this poorer recovery of the PET + LVEF was associated with two MUV evolution profiles evocative of different mechanisms: (i) a prolonged active disease in the 5 PET + patients for whom the MUV increased at follow-up, in association with a slight decrease in LVEF (p = 0.08), and (ii) a more severe initial insult in the 6 other PET + patients for whom the MUV decreased at follow-up with concomitant increases in LVEF (<i>p</i> = 0.028) but these improvements started from much worse baseline LVEF and MUV (respectively, <i>p</i> = 0.022 and 0.003 vs. the other patients).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Somatostatin PET monitoring of AM unveils numerous patients with signs of a persistent inflammatory cell infiltrate 4 to 5 months after acute myocarditis. This persistence is associated with poorer recovery of cardiac function and is seemingly due to active inflammation that is either more severe at baseline or continues to expand over the following months.</p><p><b>Trial registration number:</b> NCT03347760 on clinicaltrials.gov. </p><p><b>Registration date:</b> 22–11-2017.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"70 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intriguing combination of hepatic metastatic GIST and neuroendocrine tumor in the same patient: Disease monitoring and treatment guidance through dual tracer PET/CT and biopsy
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-22 DOI: 10.1007/s00259-025-07207-0
Austin Saju, Rahul V. Parghane, Sandip Basu
{"title":"Intriguing combination of hepatic metastatic GIST and neuroendocrine tumor in the same patient: Disease monitoring and treatment guidance through dual tracer PET/CT and biopsy","authors":"Austin Saju, Rahul V. Parghane, Sandip Basu","doi":"10.1007/s00259-025-07207-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07207-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"56 7 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthetic imaging for research and education in nuclear medicine: Who's afraid of the black box? 用于核医学研究和教育的合成成像:谁害怕黑盒子?
IF 8.6 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-22 DOI: 10.1007/s00259-025-07214-1
Luca Urso, Luigi Manco, Luca Filippi
{"title":"Synthetic imaging for research and education in nuclear medicine: Who's afraid of the black box?","authors":"Luca Urso, Luigi Manco, Luca Filippi","doi":"10.1007/s00259-025-07214-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07214-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-22 DOI: 10.1007/s00259-025-07203-4
Sejal Chopra, Jaya Shukla, Priyavrat Purohit, Umanath Adhikari, Frank Roesch, Euy Sung Moon, Yogesh Rathore, Nivedita Rana, Sanjay Kumar Bhadada, Bhagwant Rai Mittal, Rama Walia
{"title":"Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways","authors":"Sejal Chopra, Jaya Shukla, Priyavrat Purohit, Umanath Adhikari, Frank Roesch, Euy Sung Moon, Yogesh Rathore, Nivedita Rana, Sanjay Kumar Bhadada, Bhagwant Rai Mittal, Rama Walia","doi":"10.1007/s00259-025-07203-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07203-4","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Introduction&lt;/h3&gt;&lt;p&gt;Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) in the adrenocortical carcinoma (ACC) microenvironment may be used as potential therapeutic targets. This study investigated the diagnostic potential of four FAPi derivatives i.e. DOTA-FAPi-46 (FAPi46), DOTA.SA.FAPi (SA.FAPi), DATA&lt;sup&gt;5m&lt;/sup&gt;&lt;sub&gt;.&lt;/sub&gt;SA.FAPi (DATA.FAPi) and DATA&lt;sup&gt;5m&lt;/sup&gt;&lt;sub&gt;.&lt;/sub&gt;C4.FAPi (C4.FAPi) and compared with standard-of-care &lt;sup&gt;18&lt;/sup&gt;F-FDG (FDG) in ACC.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;Thirty histopathological proven cases of localized or metastatic ACC were recruited for both FDG and FAPi PET (number of patients (n) = 5 for SA.FAPi, n = 5 for DATA.FAPi, n = 5 for C4.FAPi and n = 15 for FAPi46). For biodistribution, standardized uptake values (SUV’s) were computed by delineating region-of-interest on various body organs. For comparative analysis in disease identification, lesion tracer uptake was quantified using standardized uptake values corrected for lean body mass (SUL), tumor-to-background ratio (TBR), total lesion glycolysis (TLG for FDG) and total lesion FAP expression (TLF for FAPi).&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;In overall analysis, both FAPi and FDG PET exhibited comparable mean SUL&lt;sub&gt;peak&lt;/sub&gt; [FAPi 4.3 (8.0–1.7) vs FDG 3.9 (8.1–2.5), p-0.271], mean SUL&lt;sub&gt;avg&lt;/sub&gt; [2.2 (4.3–1.2) vs 2.2 (3.4–1.3), p-0.897] and mean TBR [1.8 (3.2–1.2) vs 1.9 (2.7–1.2), p-0.696]. In volumetric analysis, comparable mean TLF and mean TLG was noted for the cohort [9.3 (53.7–4.5) vs 11.8 (33.0–4.3), p-0.107]. Sub-categorical analysis demonstrated complete concordant findings for both radiotracers in detection of all primary lesions, nodal lesions and distant metastases in lung and peritoneum with discordant findings in liver (22%) and skeletal lesions (33%). For lesion detection, DATA.FAPi and FAPi46 showed 100% concordance with FDG scan findings in metastatic disease. SA.FAPi exhibited 33% discordance by detecting an additional skeletal lesion, while C4.FAPi had 10% discordance, missing one liver lesion identified by FDG. Three &lt;sup&gt;68&lt;/sup&gt; Ga-FAP derivatives (SA.FAPi, DATA.FAPi, and C4.FAPi) exhibited similar biodistribution, with uptake in the salivary glands, thyroid, liver, pancreas, muscles, and kidneys, and variable uptake in the lacrimal glands, extra-ocular muscles, oral mucosa, and uterus. In contrast, FAPi46 physiological expression was noted in salivary glands and muscles, with no uptake in other organs. Pancreatic uptake was highest for SA.FAPi (SUVmean 11.8), DATA.FAPi (12.1), and C4.FAPi (10.8), while FAPi46 had the lowest (1.7). Conversely, FAPi46 exhibited the highest muscle uptake (SUVmean 4.3) compared to SA.FAPi (1.7), DATA.FAPi (1.4), and C4.FAPi (1.0).&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Conclusion&lt;/h3&gt;&lt;p&gt;All the existing FAP inhibitor molecules were comparable to FDG PET for mapping disease spread and a","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"46 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-21 DOI: 10.1007/s00259-025-07177-3
Clemens Mingels, Mohammad H. Madani, Fatma Sen, Hande Nalbant, Jonathan W. Riess, Yasser G. Abdelhafez, Ahmadreza Ghasemiesfe, Axel Rominger, Michele Guindani, Ramsey D. Badawi, Benjamin A. Spencer, Lorenzo Nardo
{"title":"Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT","authors":"Clemens Mingels, Mohammad H. Madani, Fatma Sen, Hande Nalbant, Jonathan W. Riess, Yasser G. Abdelhafez, Ahmadreza Ghasemiesfe, Axel Rominger, Michele Guindani, Ramsey D. Badawi, Benjamin A. Spencer, Lorenzo Nardo","doi":"10.1007/s00259-025-07177-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07177-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Our aim was to characterize the diagnostic accuracy indices for nodal (N)-staging with [<sup>18</sup>F]FDG Total-Body (TB) and short-axial field-of-view (SAFOV) PET/CT in non-small cell lung cancer (NSCLC) patients referred for staging or restaging.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this prospective single center cross-over head-to-head comparative study 48 patients underwent [<sup>18</sup>F]FDG TB and SAFOV PET/CT on the same day. In total 700 lymph node levels (1R/L, 2R/L, 3a/p, 4R/L, 5, 6, 7, 8R/L, 9R/L, 10-14R/L) of 28 patients could be correlated to a composite reference standard (histopathological correlation, imaging after localized or systemic treatment), which allowed determination of true positive (TP), false positive (FP), true negative (TN) and false negative (FN) lesions. Lymph nodes were characterized semi-quantitatively by maximum standardized uptake value (SUV<sub>max</sub>), tumor-to-background ratio (TBR), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) leading to threshold for each scanner.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>TB and SAFOV PET/CT showed high diagnostic accuracy indices for patient-based N-staging. Sensitivity and specificity were 86.0% (CI: 77.0–95.0%) and 98.3% (CI: 97.3–99.3%) for TB; 77.2% (CI: 66.3–88.1%) and 97.4% (CI: 96.1–98.6%) for SAFOV PET. Positive predictive value was higher for TB (81.7%, CI: 71.9–91.5%) compared to SAFOV PET (72.1%, CI: 60.9–83.4%). However, this finding was not statistically significant (<i>p</i> = 0.08). Negative predictive values for TB (98.6%, CI: 97.9–99.6%) and SAFOV PET/CT (98.0%, CI: 96.9–99.1%) were comparable. Overall, NSCLC N-staging was affected in six cases on SAFOV and only in one case on TB PET/CT. Semi-quantitative analysis revealed a threshold of SUV<sub>max</sub> 3.0 to detect TP lesions on both scanners. However, TBR, MTV and TLG thresholds were lower on TB compared to SAFOV PET (TBR: 1.2 vs. 1.7, MTV: 0.5 ml vs. 1.0 ml and TLG: 1.0 ml vs. 3.0 ml).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>TB and SAFOV PET/CT showed high diagnostic accuracy indices for N-staging in NSCLC patients. Sensitivity and PPV on TB PET/CT were slightly higher, compared to SAFOV PET/CT without statistical significance. However, TB PET/CT showed lower rate of incorrect N-staging and lower semi-quantitative thresholds for the detection positive mediastinal lymph nodes. Therefore, TB PET/CT might be advantageous in detecting small and low [<sup>18</sup>F]FDG-avidity mediastinal lymph node metastases in NSCLC patients.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"34 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New compartment model for hepatic blood flow quantification in humans from 15O-water PET images
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-21 DOI: 10.1007/s00259-025-07210-5
Oona Rainio, Juhani Knuuti, Riku Klén
{"title":"New compartment model for hepatic blood flow quantification in humans from 15O-water PET images","authors":"Oona Rainio, Juhani Knuuti, Riku Klén","doi":"10.1007/s00259-025-07210-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07210-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Different compartment models are commonly used to derive crucial information about blood flow, metabolism, and oxygenation from the results of a dynamic positron emission tomography (PET) scan. However, compared to blood flow in many other organs of interest, the hepatic blood flow (HBF) quantification is challenging due to the dual blood supply of liver from both the hepatic artery and the portal vein (PV). Here, we introduce a new model that can be used to estimate the HBF in combination with an automatic volume of interest selection method.</p><h3 data-test=\"abstract-sub-heading\">Materials and methods</h3><p>By using the <span>(^{15})</span>O-water PET data of 57 patients, we extract the mean time-activity curves (TACs) from aorta, hepatic PV, liver, and spleen with help of an automated computer tomography-based segmentation tool and systematically fit our new compartment model and three earlier compartment models from literature to the TACs. After this, we compare the model performance with mean relative error (MRE), mean squared error, and Akaike’s information criteria with one-sided Wilcoxon signed-rank tests. After determining the best model, we study possible HBF differences caused by age, sex, and weight with Mann-Whitney U test and Pearson’s correlations coefficient.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We obtained the mean arterial HBF of 0.299±0.168 mL/min/mL, the mean portal HBF of 0.930±0.520 mL/min/mL, and the total HBF of 1.229±0.612 mL/min/mL with our new model. Based on earlier research, both these estimates and also the results of two earlier versions of the original dual-input model are realistic. Out of these three models, our proposed model performed the best in terms of MRE (p-values<span>(le )</span>0.001). According to our results, there are no significant sex- or age-based differences but there is moderate positive correlation between the arterial and portal HBFs and negative correlation between the total HBF and the weight of patients.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The HBF can effectively be estimated from <span>(^{15})</span>O-water PET data with our new model in combination with robust segmentation by TotalSegmentator. Due to the fact that potential underestimation of the PV concentration caused by the small size of this vessel might lead to overestimation of the HBF, more research would be beneficial to validate these methods further. Our results suggests that there is a negative trend between the HBF and the weight, though this might be related to the underlying conditions of the patients.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"88 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC 对接受[177Lu]Lu-PSMA治疗的mCRPC患者进行[18F]FDG和PSMA-PET评估的预后价值
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-21 DOI: 10.1007/s00259-025-07198-y
Tugce Telli, Leonor Lopes, Madeleine Karpinski, Kim M. Pabst, Viktor Grünwald, Kuangyu Shi, Boris Hadaschik, Claudia Kesch, Lale Umutlu, Ken Herrmann, Robert Seifert, Wolfgang P. Fendler
{"title":"Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC","authors":"Tugce Telli, Leonor Lopes, Madeleine Karpinski, Kim M. Pabst, Viktor Grünwald, Kuangyu Shi, Boris Hadaschik, Claudia Kesch, Lale Umutlu, Ken Herrmann, Robert Seifert, Wolfgang P. Fendler","doi":"10.1007/s00259-025-07198-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07198-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To improve [<sup>177</sup>Lu]Lu-Prostate-specific membrane antigen therapy (LuPSMA) selection, this study investigates the prognostic value of PSMA and 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose ([<sup>18</sup>F]FDG)-PET in metastatic castration-resistant prostate cancer (mCRPC) patients considered for LuPSMA therapy.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We conducted a retrospective analysis in 152 mCRPC patients referred for LuPSMA therapy who underwent PSMA and [<sup>18</sup>F]FDG-PET/CT. Of these, 104 patients (68.4%) underwent LuPSMA therapy, while 48 (31.6%) received other standard of care (SOC). PET/CT analyses included visual assessment and semiquantitative measurements. Clinical and laboratory parameters were recorded. Overall survival (OS) and PSA response (decline &gt; 50%) were primary and secondary endpoints, respectively.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Baseline [<sup>18</sup>F]FDG-derived total tumor volume was the only independent predictor of overall survival both in patients subsequently treated with LuPSMA (HR 1.28 [95%CI 1.02—1.61]; p = 0.03) or in those under other SOC (HR 1.61 [95%CI 1.02—2.56]; p = 0.04), respectively. In other SOC patients, additional independent predictors of OS were total lesion PSMA uptake (PSMA-TL; HR 1.14 [95%CI 1.03–1.26]; p = 0.01), [<sup>18</sup>F]FDG mean SUV (HR 20.88 [95%CI 1.2–364.74]; p = 0.04), and [<sup>18</sup>F]FDG total lesion glycolysis (HR 1.61 [95%CI 1.02–2.56]; p = 0.04). In LuPSMA patients, PSMA-PET SUVmean was a significant independent predictor of PSA decline ≥ 50% (OR 2.97 [95%CI 1.27–8.16]; p = 0.02).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>PSMA-PET and [<sup>18</sup>F]FDG-PET provide imaging biomarkers of outcome in candidates for LuPSMA. FDG-PET total tumor volume was an independent predictor of overall survival in candidates for LuPSMA therapy, irrespective of subsequent treatment decision. PSMA-PET SUVmean was associated with biochemical response to LuPSMA. Dual tracer imaging should further be assessed in prospective trials for mCRPC treatment guidance.\u0000</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer 肺癌 PET/CT 中 PD-L1 表达与 [18F]FAPI 和 [18F]FDG 摄取之间的关系
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-21 DOI: 10.1007/s00259-025-07201-6
Jingjie Qin, Chao Han, Haoqian Li, Zhendan Wang, Xudong Hu, Lanping Liu, Shouhui Zhu, Jingjing Zhao, Yuhong Sun, Yuchun Wei
{"title":"Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer","authors":"Jingjie Qin, Chao Han, Haoqian Li, Zhendan Wang, Xudong Hu, Lanping Liu, Shouhui Zhu, Jingjing Zhao, Yuhong Sun, Yuchun Wei","doi":"10.1007/s00259-025-07201-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07201-6","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Purpose&lt;/h3&gt;&lt;p&gt;To investigate the correlation between [&lt;sup&gt;18&lt;/sup&gt;F] labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/computed tomography (CT) uptake and programmed death ligand 1 (PD-L1) expression in lung cancer and evaluate the predictive value of [&lt;sup&gt;18&lt;/sup&gt;F]FAPI PET/CT for PD-L1 expression compared with [&lt;sup&gt;18&lt;/sup&gt;F]fluorodeoxyglucose ([&lt;sup&gt;18&lt;/sup&gt;F]FDG) PET/CT.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;This single-center retrospective study consecutively enrolled patients with pathologically confirmed lung cancer who underwent [&lt;sup&gt;18&lt;/sup&gt;F]FAPI and [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT scans within 2 weeks, with a minimum interval of 20 h. PD-L1 expression was assessed using immunohistochemistry and stratified into three groups. PET/CT uptake parameters included the maximum standard uptake value (SUV&lt;sub&gt;max&lt;/sub&gt;) in the biopsy tumor or mediastinal metastasis lymph nodes area and the mean SUV&lt;sub&gt;s&lt;/sub&gt; (SUV&lt;sub&gt;mean&lt;/sub&gt;) of normal tissue (lung and blood). The ratios of SUV&lt;sub&gt;max&lt;/sub&gt; to the SUV&lt;sub&gt;mean&lt;/sub&gt; for each normal tissue were denoted as the tumor-to-background ratios (TBR&lt;sub&gt;lung&lt;/sub&gt; and TBR&lt;sub&gt;blood&lt;/sub&gt;). All statistical analyses were conducted using IBM SPSS Statistics. Normality was assessed, and for non-normally distributed data, the Kruskal-Wallis and Mann-Whitney U tests were applied. Associations between variables were evaluated using Spearman’s rank correlation. All tests were two-sided, with a &lt;i&gt;P&lt;/i&gt;-value &lt; 0.05 considered statistically significant.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;Among the 75 cases included on the final analysis, the TBR&lt;sub&gt;blood&lt;/sub&gt; and TBR&lt;sub&gt;lung&lt;/sub&gt; derived from [&lt;sup&gt;18&lt;/sup&gt;F]FAPI PET/CT were significantly positively correlated with PD-L1 expression (&lt;i&gt;r&lt;/i&gt; = 0.32, &lt;i&gt;P&lt;/i&gt; &lt; 0.01; &lt;i&gt;r&lt;/i&gt; = 0.26, &lt;i&gt;P&lt;/i&gt; &lt; 0.05). Additionally, cases with high PD-L1 expression showed significantly higher [&lt;sup&gt;18&lt;/sup&gt;F]FAPI uptake values (mean TBR&lt;sub&gt;lung&lt;/sub&gt;=36.16; mean TBR&lt;sub&gt;blood&lt;/sub&gt;=10.75) compared with those with low PD-L1 expression (mean TBR&lt;sub&gt;lung&lt;/sub&gt;=25.10; mean TBR&lt;sub&gt;blood&lt;/sub&gt;=8.04). No statistically significant correlation was observed between [&lt;sup&gt;18&lt;/sup&gt;F]FDG uptake values and PD-L1 expression level. Receiver operating characteristic analysis identified TBR&lt;sub&gt;blood&lt;/sub&gt; on [&lt;sup&gt;18&lt;/sup&gt;F]FAPI PET/CT with a cutoff value of 7.76 (area under the curve = 0.68, &lt;i&gt;P&lt;/i&gt; &lt; 0.01, sensitivity = 75%, and specificity = 53.49%) as a significant predictor of the level of PD-L1 expression.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Conclusion&lt;/h3&gt;&lt;p&gt;[&lt;sup&gt;18&lt;/sup&gt;F]FAPI uptake was positively correlated with PD-L1 expression in lung cancer. The combination of [&lt;sup&gt;18&lt;/sup&gt;F]FAPI PET/CT and PD-L1 expression may offer a more comprehensive approach to assessing the response of lung cancer to immunotherapy.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"37 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-20 DOI: 10.1007/s00259-025-07176-4
Solène Malmon, Mad-Helenie Elsensohn, Catherine Thieblemont, Franck Morschhauser, Olivier Casasnovas, Marc André, Steven Le Gouill, Yassine Al Tabaa, Paul Bland Durand, Clement Bailly, Veronique Edeline, Lavinia Vija, Laetitia Vercellino, Romain Ricci, Salim Kanoun, Anne-Ségolène Cottereau
{"title":"Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials","authors":"Solène Malmon, Mad-Helenie Elsensohn, Catherine Thieblemont, Franck Morschhauser, Olivier Casasnovas, Marc André, Steven Le Gouill, Yassine Al Tabaa, Paul Bland Durand, Clement Bailly, Veronique Edeline, Lavinia Vija, Laetitia Vercellino, Romain Ricci, Salim Kanoun, Anne-Ségolène Cottereau","doi":"10.1007/s00259-025-07176-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07176-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study compared the prognostic value of total metabolic tumor volume (TMTV) in lymphoma measured with the recently proposed SUV4.0 segmentation threshold versus the 41% SUVmax across LYSA trials and its impact on intensity and dissemination PET features.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A total of 1960 baseline PET/CT scans of Diffuse Large B cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) patients were collected. After a semi-automatic preselection of region of interest, two different segmentation threshold were applied: 41% SUVmax (TMTV<sub>41%</sub>) and SUV &gt; 4.0 (TMTV<sub>4.0</sub>).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The correlation between TMTV<sub>4.0</sub> and TMTV<sub>41%</sub> was ρ = 0.90 for DLBCL, ρ = 0.65 for FL and ρ = 0.60 for HL. For SUVmax, SUVpeak, Dmax and Dbulk features, a strong correlation was observed with ρ &gt; 0.95 whatever the lymphoma subtypes. The predictability of TMTV was high and comparable for the two methods with superimposable confidence intervals for the three subtypes. At the 90th percentile TMTV value, the predicted 7-year PFS was 51.13% with TMTV<sub>4.0</sub> vs. 49.7% with TMTV<sub>41%</sub> for DLBCL patients, 45.5% vs. 39.8% for FL patients, and 82.6% vs. 80.5% for HL patients. A minority of patients showed a predicted PFS deviation &gt; 10% between the two methods: 2.33% in DLBCL, 6.51% in FL and 1% in HL.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>TMTV measured with the SUV4.0 threshold provides a comparable PFS prediction than the 41%SUVmax method supporting its routine adoption particularly in the diffuse large B cell lymphoma subtype.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Takayasu’s arteritis imaged by a LAFOV PET/CT system: better resolution leads to greater diagnostic certainty
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-03-20 DOI: 10.1007/s00259-025-07192-4
Sofie Rytter, André Henrique Dias, Ole Lajord Munk, Lars Christian Gormsen
{"title":"Takayasu’s arteritis imaged by a LAFOV PET/CT system: better resolution leads to greater diagnostic certainty","authors":"Sofie Rytter, André Henrique Dias, Ole Lajord Munk, Lars Christian Gormsen","doi":"10.1007/s00259-025-07192-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07192-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"24 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信